FDA Grants Fast Track Designation to Alzheimer's Disease Drug Candidate AZD-103/ELND005
Advertisement
Transition Therapeutics Inc. announced that the United States food and Drug Administration has granted Fast Track designation to investigational drug candidate AZD-103/ELND005, being developed in collaboration with Elan Corporation, plc. for the treatment of Alzheimer's disease.
AZD-103/ELND005 is currently being evaluated in multiple Phase I clinical studies, and the companies anticipate starting Phase II clinical studies around the end of 2007.